Asset Publisher

Evaluation of Strategies for Yaws Eradication

Yaws eradication

The Barcelona Institute for Global Health (ISGlobal) research team has developed the tools needed to definitively eradicate yaws from the planet: a diagnosis of yaws can now be confirmed using a new test based on a single drop of blood, and a single dose of azithromycin (an oral antibiotic) has been shown to be effective in curing the infection. http://www.who.int/yaws/photos/en/

The findings of the studies jump started the NTD community in action and prompted the World Health Organization (WHO) to target yaws for Global Eradication by 2020.

The objective of our new project is to evaluate the new WHO-strategy to stop yaws transmission which involves mass treatment with single dose oral azithromycin of the entire population. If the new strategy proves effective, countries will be free of the disease in one or two years after implementation.

What is the Ultimate Goal?

The goal is to eradicate yaws DEFINITIVELY WORLDWIDE in the short to medium term (10 years).

Yaws eradication will need a donation of 40 million treatments, with a cost of 0.50 Euro per treatment, and fundings to distribute the pill. Representatives of the countries where yaws is still endemic have made a commitment to fight this disease.

What is Yaws?

Documentary: War Against Yaws

The Broadcaster producer has started the filming of a documentary on Dr Oriol Mitjà's story: http://www.broadcaster.cat/pian

Project Funders

Newcrest Mining Limited

International SOS - Niugini

External links

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61624-3/fulltext

http://www.who.int/yaws/photos/en/index2.html

http://www.theguardian.com/global-development/2014/feb/21/yaws-bacterial-skin-disease-who-donated-antibiotics

Our Team

Other projects

See Past Projects

COMBACTE

Combating Bacterial Resistance In Europe

GAMA

Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

MAMAH

Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women

INTE-AFRICA

Integrating and decentralizing diabetes and hypertension services in Africa

ICARIA

Improving Care through Azithromycin Research for Infants in Africa

PreFIT

Predicting the Future: Incipient Tuberculosis

ANTICOV

Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19

Stool4TB

Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

TB-RECONNECT

Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status

SToolNIH

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring

END-VOC

ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)

TwinAir

Digital Twins Enabled Indoor Air Quality Management for Healthy Living

ENDÈMIC

Community knowledge generation through scientific culture, urban ecology and art

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

Hepatitis C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.

FLAVOBAC

Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias